In conclusion, our integrated approach identified CDK1 as a central regulatory hub in ovarian epithelial cancer and revealed Naringin as a promising dual-target inhibitor of both CDK1 and WEE1. This evidence concerns the gene WEE1 and ovarian carcinoma.